Personalized therapy for common variable immunodeficiency

Area of Science:

• Immunology
• Genetics
• Medical Diagnostics

Background:

• Common variable immunodeficiency (CVID) is a clinical diagnosis from the 1970s.
• Pathophysiology is understood in only 25% of CVID patients, despite advances in immunology and genetics.
• Recent progress allows for more specific, individualized therapies.

Purpose of the Study:

• To review current understanding and treatment of CVID.
• To highlight recent advances in pathophysiology and targeted therapies.
• To discuss future directions in CVID management.

Main Methods:

• Literature review.
• Author's clinical experience.

Main Results:

• Immunoglobulin therapy has been standard for over 50 years, with various products and administration routes.
• Stem cell therapy is increasingly viable for severe immune dysregulation in CVID.
• Genetic and molecular understanding enables targeted therapies (small molecules, biologics) for specific CVID subtypes.

Conclusions:

• Further research into CVID pathophysiology will drive new targeted treatments.
• Development of biologics and small-molecule immune modulators will expand therapeutic options.
• Future CVID management will likely involve more personalized and precise interventions.